Tempus AI Revenue Surges 83% to $1.27 Billion Driven by Strong Diagnostics Demand

2026-01-11 companies

Chicago, Monday, 12 January 2026.
Tempus AI reports preliminary 2025 revenue of $1.27 billion, marking an 83% year-over-year surge. Diagnostics revenue more than doubled, driving performance that CEO Eric Lefkofsky states exceeded initial expectations.

Diagnostics Segment Lead Growth

The company’s robust performance was primarily anchored by its Diagnostics segment, which generated approximately $955 million in revenue for the full year, representing a significant growth of roughly 111% compared to the previous year [1][2]. This surge was underpinned by substantial increases in testing volumes; specifically, oncology testing volume rose by approximately 26%, while hereditary testing volume grew by roughly 29% [1][2]. These figures highlight the increasing adoption of Tempus AI’s genomic profiling and diagnostic tools in clinical settings.

Data and Applications Expansion

Complementing the diagnostics arm, the Data and Applications segment reported revenue of approximately $316 million for 2025, a year-over-year increase of about 31% [1][2]. Within this segment, the ‘Insights’ product line—which involves data licensing—saw a growth rate of approximately 38% [1][2]. Eric Lefkofsky, Founder and CEO, characterized 2025 as an “exceptional year” where both product lines outperformed the company’s internal projections [1][2].

Quarterly Acceleration and Historical Context

The momentum appeared to accelerate in the final months of the year. For the fourth quarter ended December 31, 2025, Tempus recorded revenue of approximately $367 million, an 83% increase from the same period the prior year [1][5]. The Data and Applications segment specifically saw a sharp uptick in the fourth quarter, with Insights revenue growing approximately 68% [2]. When viewed against the company’s 2024 full-year revenue of $693.40 million [3], the 2025 total of $1.27 billion represents a massive expansion of the business, adding 576.6 million in top-line revenue in a single year.

Strategic Outlook

Looking ahead, Tempus AI is set to provide further details on its strategic direction. The company is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, which begins today, January 12, 2026 [4]. Investors awaiting the complete, audited financial profile for the fourth quarter and full year 2025 can expect the company to report these figures during its earnings call in February 2026 [1][2].

Sources

Tempus AI Financial Results